Univ.-Prof. Dr. Kurt Huber

Work address
Wilhelminenhospital
3rd Medical Department with Cardiology
Montleartstraße 37
1160 Vienna, Austria

Phone: +43 (0)1 49150 - 2301
Fax: +43 (0)1 49150 - 2309
E-Mail: kurt.huber@wienkav.at

Know-how and research interests
My major research interest are the pathophysiology, diagnosis, and treatment of ACS (UA, NSTEMI, STEMI); mechanisms of restenosis and stent thrombosis; the plasmin activation system in disease; reperfusion strategies in STEMI, STEMI networks; anticoagulation and antiplatelet therapy in cardiovascular diseases; the role of platelet function testing; statins; diabetes in heart; and SNPs research (for CYP 450 isoenzymes), respectively.

Research topic (general title)

Antithrombotic Therapy in Acute Coronary Syndromes and Atrial Fibrillation.

Techniques and infrastructure of the research group

• Platelet Function Measurement (MEA, VASP, VERIFY NOW)
• Biomarker Measurement (Copeptin, Adrenomedullin, BNP)
• Outpatients ward specific for clinical studies
• 3 full-time research contracts, 5 past-time research contracts (PhD studies)

5 selected publications

• Huber K, Connolly SJ, Kher A, Christory F, Dan GA, Hatala R, Kiss RG, Meier B, Merkely B, Pieske B, Potpara T, Stępińska J, Klun NV, Vinereanu D, Widimský P. Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. Int J Clin Pract. 2013 Jun;67(6):516-26. doi:10.1111/ijcp.12147. Epub 2013 Apr 5.
  
  
• Huber K, Goldstein P, Danchin N, Fox KA, Welsh R, Granger CB, Henry T, Gersh BJ. Enhancing the efficacy of delivering reperfusion therapy: A European and North American experience with ST-segment elevation myocardial infarction networks. Am Heart J. 2013 Feb;165(2):123-32. doi: 10.1016/j.ahj.2012.10.032. Epub 2012 Dec 4. PMID: 23351814
  
  
• Huber K, Lip GY. Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes. Thromb Haemost. 2013 Jul 1;110(1):11-3. doi: 10.1160/TH13-06-0453. Epub 2013 Jun 7. PMID: 23743615
  
  
• Huber K, Schrör K. High on-treatment platelet reactivity - why should we be concerned? Thromb Haemost. 2013 May 2;109(5):789-91. doi: 10.1160/TH13-04-0281. Epub 2013 Apr 11.
  
  
• Freynhofer MK, Bruno V, Willheim M, Hübl W, Wojta J, Huber K. Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: Does standardisation matter? Thromb Haemost. 2012 Mar 1;107(3):538-44. Epub 2012 Jan 25. PMID: 22274403